USAMRDC announces FDA licensure for severe malaria treatment

(Walter Reed Army Institute of Research) The US Army Medical Research and Development Command announced today that the US Food and Drug Administration granted marketing approval for Artesunate for Injection, an initial treatment for severe malaria. The drug was developed under current Good Manufacturing Practices by the Walter Reed Army Institute of Research and the US Army Medical Materiel Development Activity, subordinate commands of USAMRDC. The only other FDA-approved treatment option, intravenous quinidine, was discontinued in 2019.
Source: EurekAlert! - Infectious and Emerging Diseases - Category: Infectious Diseases Source Type: news